- Home
- TGTX vs VKTX Comparison
TGTX vs VKTX Comparison
Compare TGTX & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGTX | VKTX |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.1B |
| IPO Year | 2008 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TGTX | VKTX |
|---|---|---|
| Price | $33.85 | $29.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $49.80 | ★ $95.86 |
| AVG Volume (30 Days) | 1.6M | ★ 2.2M |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1746.67 | N/A |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $2,785,000.00 | N/A |
| Revenue This Year | $49.08 | N/A |
| Revenue Next Year | $26.69 | N/A |
| P/E Ratio | $12.22 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.37 | $22.96 |
| 52 Week High | $40.99 | $43.15 |
Technical Indicators
Market Signals| Indicator | TGTX | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.29 | 33.86 |
| Support Level | $32.95 | $23.08 |
| Resistance Level | $35.33 | $35.85 |
| Average True Range (ATR) | 1.28 | 1.56 |
| MACD | -0.43 | -0.53 |
| Stochastic Oscillator | 13.01 | 12.67 |
Price Performance
Historical ComparisonAbout TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.